Table 5. Distribution of KRAS exon 2 mutation genotypes in various clinical stages of patients.
| Mutations | Clinical stage | Total number |
|---|---|---|
| CD166 positive CRC | ||
| c.35G>A | TNM stage III | 12 |
| TNM stage IV | 6 | |
| c.35G>T | TNM stage III | 5 |
| TNM stage II | 3 | |
| c.34G>A | TNM stage II | 3 |
| CD166 negative CRC | ||
| c.35G>A | TNM stage II | 3 |
| TNM stage I | 2 | |
| c.35G>T | TNM stage III | 2 |
| CD166 positive CAD | ||
| c.35G>A | Severe dysplasia | 3 |
| Moderate dysplasia | 3 | |
| c.35G>T | Moderate dysplasia | 5 |
| CD166 negative CAD | ||
| c.35G>A | Severe dysplasia | 1 |
| c.38G>A | Moderate dysplasia | 2 |
| c.34G>A | Mild dysplasia | 1 |